The Impact Of Modified Glasgow Prognostic Scale As A Predictor Of Survival Advantage By Folfirinox In Metastatic Pancreatic Cancer.

440 Background: The superiority of FOLFIRINOX (FFX) therapy over gemcitabine (Gem) alone in patients with metastatic pancreatic cancer (mPC) has been demonstrated in ACCORD11. However, this combination regimen is associated with relevant toxicity and predictors for response to therapy are warranted. The aim of this study is to determine the prognostic factors associated with an indication for FFX therapy in patients with mPC. Methods: The current study included data from all consecutive patients who were diagnosed as mPC at our hospital between September 2007 and December 2014. Selection criteria were as follows: patients who 1) had histologically confirmed pancreatic adenocarcinoma, 2) were diagnosed as having metastatic disease, and 3) received first-line chemotherapy with Gem alone or FFX. We examined the prognostic markers, such as derived neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, modified Glasgow prognostic scale (mGPS), ECOG Performance Status (PS), CA19-9 level and number of metastati...